Why capillary electrophoresis still matters in modern biopharma by Roxana McCloskey | Jun 9, 2026 | Biopharma, Blogs, CERead time: 2 minutes When molecules evolve, analytical certainty must keep up Biopharma development has changed dramatically over the past decade. Molecules are larger, more complex, and more diverse than ever, from highly engineered proteins and conjugates to long...
Where does capillary electrophoresis fit across drug development? by Roxana McCloskey | Jun 9, 2026 | Biopharma, Blogs, CERead time: 4 minutes Capillary electrophoresis (CE) is not confined to a single point in the drug development lifecycle. Its value comes from the ability to deliver high‑resolution, reproducible separations that remain relevant as analytical questions evolve, from...
Why middle‑down and subunit MS analyses powered by EAD are transforming biopharmaceutical characterization by Roxana McCloskey | May 15, 2026 | Biopharma, BlogsRead time: 6 minutes As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides...
Why electron-activated dissociation (EAD) improves sequence variant analysis in biopharma LC/MS workflows by Roxana McCloskey | Apr 29, 2026 | Biopharma, BlogsRead time: 4 minutes In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by...
How NFD improves impurity detection and peak integration in CE SDS workflows by Roxana McCloskey | Apr 28, 2026 | Biopharma, BioPhase 8800 system, BlogsCE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for...
CE‑SDS in monoclonal antibody therapeutic development by Roxana McCloskey | Mar 31, 2026 | Biopharma, BioPhase 8800 system, BlogsRead time: 3 minutes A familiar assay with a new way to see more. In monoclonal antibody (mAb) development, assessment of purity and integrity of the protein in question is critical. CE‑SDS is the gold standard assay and is routinely run from analytical development...
Guide decisions during cell line development with more information at the intact level by Roxana McCloskey | Mar 28, 2024 | Biopharma, Blogs, Intabio ZT system, ZenoTOF 7600 systemRead time: 5 minutes Monitoring product quality attributes (PQAs) throughout monoclonal antibody (mAb) development is vital to ensuring drug safety and efficacy. By adopting orthogonal analytical techniques and integrating new technologies that have the potential to...
Changing the game of drug development with the Intabio ZT system by Roxana McCloskey | Oct 4, 2023 | Biopharma, Blogs, ZenoTOF 7600 systemRead time: 5minutes What better to learn how a new technology like icIEF-UV/MS is advancing drug development than hearing from the labs that are using it? Kristen Nields, Senior Scientist at The Janssen Pharmaceutical Companies of Johnson & Johnson sat down with...